Inflammatory Bowel Disease (IBD) Diagnostic - Market Insights, Competitive Landscape, and Market Forecast - 2030

Inflammatory Bowel Disease (IBD) Diagnostic - Market Insights, Competitive Landscape, and Market Forecast - 2030

Inflammatory Bowel Disease (IBD) Diagnostic Market By Product Type (Instruments, Reagents & Kits), Test Type ( Blood Test, Fecal Test, Endoscopy, Imaging, Biopsy), Disease Type (Ulcerative Colitis And Crohn’s Disease), End-User (Hospitals And Clinics, Diagnostic And Imaging Centers, And Others), And Geography (North America, Europe, Asia-Pacific, And Rest Of The World) is expected to grow at a steady CAGR forecast till 2030 owing to the rising prevalence of inflammatory bowel disease (IBD) and its risk factors globally

The global Inflammatory Bowel Disease (IBD) Diagnostic market is estimated to grow at a CAGR of 5.13% during the forecast period from 2024 to 2030. The demand for Inflammatory Bowel Disease (IBD) Diagnostic is primarily being boosted owing to the rising prevalence of inflammatory bowel disease globally, the increasing number of risk factors for inflammatory bowel diseases, and rapid research & recent developments activities in gastrointestinal science studies, among others during the forecast period from 2024 to 2030.

Inflammatory Bowel Disease (IBD) Diagnostic Market Dynamics:

As per data from the recent research article by BMC Medical Research Methodology (2023) IBD is expected to affect more than 7 million individuals in Europe and the United States by 2030, with a prevalence of more than 0.3% in North America, Oceania, and several European nations. The latest data presented by Crohn’s & Colitis UK says that approximately 25,000 people have been diagnosed with IBD in the UK during 2020, this translates to 66 people being diagnosed with IBD every day in the UK.

The 2022 data published by the Global Cancer Observatory stated that there were about 126,724 new cases of stomach cancer reported in Japan in 2022. As per the same source about 14,088 cases of stomach cancer were reported in 2022 in Germany and this number is expected to reach up to 18.7 thousand by 2040.

The increasing cases of IBD cases globally would significantly bolster the demand for more number of IBD diagnostic procedures to be carried out, in the upcoming years. Therefore, considering the large patient pool associated with inflammatory bowel diseases, the market for Inflammatory Bowel Disease (IBD) Diagnostic is expected to grow significantly during the given forecast period.

However, the lack of healthcare infrastructure in countries, and the lack of awareness among people may act as significant restraints that are expected to limit the growth of the Inflammatory Bowel Disease (IBD) Diagnostic market during the forecast period.

Inflammatory Bowel Disease (IBD) Diagnostic Market Segment Analysis:

Inflammatory Bowel Disease (IBD) Diagnostic Market by Product Type (Instruments, Reagents & Kits), Test Type ( Blood Test, Fecal Test, Endoscopy, Imaging, Biopsy), Disease Type (Ulcerative Colitis and Crohn’s Disease), End-User (Hospitals and Clinics, Diagnostic and Imaging Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the test type segment of the Inflammatory Bowel Disease (IBD) Diagnostic market, the endoscopy category is estimated to amass a significant revenue share in the Inflammatory Bowel Disease (IBD) Diagnostic market in 2023. This can be ascribed to the advantages associated with the various endoscopic methods in diagnosing, treating, and managing inflammatory bowel diseases.

Endoscopic methods including colonoscopy, esophagogastroduodenoscopy, sigmoidoscopy, and capsule endoscopy are the key diagnostic methods utilized to accurately diagnose IBD. Diagnosis through these methods helps in the easy differentiation of Crohn’s disease (CD) with that from Ulcerative Colitis (UC). Ileocolonoscopy, which is colonoscopy with ileoscopy, is considered the gold standard method for detecting and diagnosing inflammatory bowel disease. Through ileocolonoscopy, the most severely or commonly affected areas of the bowel in patients with IBD can be easily visualized.

Esophagogastroduodenoscopy is highly recommended in pediatric patients in whom IBD is suspected and it helps to establish a definitive diagnosis for both Crohn’s disease (CD) and Ulcerative Colitis (UC). Sigmoidoscopy assists in the examination of IBD in the colon and rectum. Capsule endoscopy offers visualization of the entire length of the small bowel in suspected IBD patients in a comparatively less invasive manner.

For example, PillCam™ SB 3 by Medtronic is a minimally invasive capsule endoscopy system with an ingestible camera in a capsule that allows visualization of the small bowel and assists in the diagnosis of Crohn’s disease.

Therefore, considering the advantages associated with endoscopic methods and their growing popularity among the end-users, this category is expected to generate considerable revenue, thereby pushing the overall growth of the global IBD diagnostic market during the forecast period from 2024 to 2030.

North America Is Expected To Dominate The Overall Inflammatory Bowel Disease (IBD) Diagnostic Market:

North America is expected to account for the highest proportion of the Inflammatory Bowel Disease (IBD) Diagnostic Market in 2023, out of all regions. This is due to the rising patient population associated with IBDs, the growing number of digestive disorders, increasing awareness and initiatives by key organizations, and rising clinical and research initiatives, among others that are responsible for the growth of the North America Inflammatory Bowel Disease (IBD) Diagnostic market.

As per the World Bank data 2020, there were around 2,489,362 cases of inflammatory bowel disease (IBD) in 2020 in the US and by 2030 this number is expected to rise to 3,544,480. Also, as per the Centers for Disease Control and Prevention 2022, about 3 million people are living with IBD in the United States. As per the same source, around 80,000 children are expected to be suffering from IBD in the US. This, therefore, indicates the growing need for diagnostic tools and technologies for proper diagnosis, treatment, and management of the disease.

The rising number of initiatives by the government and non-government organizations such as research funding in the region is another possible factor affecting the growth of the IBD diagnostic market.

For example, the Crohn's & Colitis Foundation is a non-profit organization involved in sponsoring basic and clinical research happening in relation to inflammatory bowel disease in the US. In addition, the American Gastroenterological Association (AGA) launched Trust Your Gut in September 2022, an awareness campaign focused at reducing the period between the onset of bowel symptoms and conversations with a healthcare professional. Such initiatives are also likely to boost demand for IBD diagnostics in the US during the forecast period.

Hence, all the above-mentioned factors are likely to contribute to the growth of the Inflammatory Bowel Disease (IBD) Diagnostic market in North America during the forecast period from 2024 to 2030.

Inflammatory Bowel Disease (IBD) Diagnostic Market Key Players:

Some of the key market players operating in the Inflammatory Bowel Disease (IBD) Diagnostic market include Medtronic, GE Healthcare, Canon Medical Systems Corporation, FUJIFILM Holdings Corporation, Hologic Inc., SternMed GmbH, Koninklijke Philips N.V., Seimens Healthineers, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Samsung Medison (Samsung Electronics Co., Ltd.), Thermofisher Scientific Inc., AbbVie Inc., TECHLAB, Inc., Svar Life Science, and others.

Recent Developmental Activities In The Inflammatory Bowel Disease (IBD) Diagnostic Market:

In April 2024, researchers from the Birmingham NIHR Biomedical Research Centre (BRC) at the University of Birmingham tested a new protocol to improve IBD diagnosis by combining clinical history with multiple home stool tests. The new protocol for diagnosing IBD aims to provide a more accurate diagnosis and reduce the strain on current testing methods, particularly colonoscopies.

In April 2023, EnLiSense CCM, a medical health wearables technology company announced that it received an investment from the Crohn’s & Colitis Foundation’s IBD Ventures program to develop EnLiSense CCM’s IBD AWARE product. IBD AWARE is an inflammation tracker targeting key biomarkers associated with inflammatory bowel disease (IBD).

In September 2022, Takeda announced the national launch of the CDPATH program, which included an innovative, validated personalized prognostic tool that used blood tests to help predict the potential risk of developing serious Crohn’s disease-related complications within three years.

Key Takeaways From The Inflammatory Bowel Disease (IBD) Diagnostic Market Report Study

Market size analysis for current Inflammatory Bowel Disease (IBD) Diagnostic Market size (2023), and market forecast for 6 years (2024 to 2030)

Top key product offerings, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global Inflammatory Bowel Disease (IBD) Diagnostic market.

Various opportunities available for the other competitors in the Inflammatory Bowel Disease (IBD) Diagnostic Market space.

What are the top-performing segments in 2023? How these segments will perform in 2030?

Which are the top-performing regions and countries in the current Inflammatory Bowel Disease (IBD) Diagnostic market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for Inflammatory Bowel Disease (IBD) Diagnostic market growth in the coming future?

Target Audience Who Can Be Benefited From This Inflammatory Bowel Disease (IBD) Diagnostic Market Report Study

Inflammatory Bowel Disease (IBD) Diagnostic product providers

Public and Private Corporate companies

Inflammatory Bowel Disease (IBD) Diagnostic-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Product Providers dealing in Inflammatory Bowel Disease (IBD) Diagnostic

Various corporates who want to know more about the Inflammatory Bowel Disease (IBD) Diagnostic Market and the latest product offerings in the Inflammatory Bowel Disease (IBD) Diagnostic Market.

Frequently Asked Questions For The Inflammatory Bowel Disease (IBD) Diagnostic Market:

1. What are Inflammatory Bowel Disease (IBD) Diagnostic?

The diagnosis of inflammatory bowel disease (IBD) with its 2 main sub-forms, Crohn's disease and ulcerative colitis, is based on clinical, endoscopic, radiologic, and histologic criteria, which is carried out and determined through various tests or a combination of tests.

2. What is the market for Inflammatory Bowel Disease (IBD) Diagnostic?

The global Inflammatory Bowel Disease (IBD) Diagnostic market is estimated to grow at a CAGR of 5.13% during the forecast period from 2024 to 2030.

3. What are the drivers for the Global Inflammatory Bowel Disease (IBD) Diagnostic market?

The Inflammatory Bowel Disease (IBD) Diagnostic Market is slated to witness prosperity owing to the rising prevalence of inflammatory bowel disease globally, the increasing number of risk factors for inflammatory bowel diseases, rapid research and recent developments in gastrointestinal science studies, among others during the forecast period from 2024 to 2030.

4. Who are the key players operating in the global Inflammatory Bowel Disease (IBD) Diagnostic market?

Some of the key market players operating in the Inflammatory Bowel Disease (IBD) Diagnostic market include Medtronic, GE Healthcare, Canon Medical Systems Corporation, FUJIFILM Holdings Corporation, Hologic Inc., SternMed GmbH, Koninklijke Philips N.V., Seimens Healthineers, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Samsung Medison (Samsung Electronics Co., Ltd.), Thermofisher Scientific Inc., AbbVie Inc., TECHLAB, Inc., Svar Life Science, and others.

5. Which region has the highest share in the Global Inflammatory Bowel Disease (IBD) Diagnostic market?

North America is expected to dominate the overall Inflammatory Bowel Disease (IBD) Diagnostic market during the forecast period from 2024 to 2030. This is due to the rising patient population associated with IBDs, the growing number of digestive disorders, increasing awareness and initiatives by key organizations, rising clinical and research initiatives, among others that are responsible for the growth of the North America Inflammatory Bowel Disease (IBD) Diagnostic market.